Should a Series A biotech company hire a fractional CRO in 2027?

Direct Answer
If your biotech company has raised a Series A (typically $8M–$15M) and is still 12–24 months from a commercial launch, you likely do not need—and cannot justify—a full-time CRO. A fractional CRO brings the same strategic depth (go-to-market planning, channel selection, KPI frameworks, investor-grade revenue forecasts) at a fraction of the cash burn. The trade-off is time: you get 8–12 days per month, not 20. That is usually sufficient for a pre-commercial or early-commercial biotech where the revenue team is 2–5 people and the primary job is designing the commercial engine, not running it at scale.
Why 2027 Changes the Calculation
The biotech funding environment in 2027 remains capital-disciplined. Series A rounds are smaller on average than the 2020–2021 peak, and investors expect a clearer path to revenue before the next raise. A full-time CRO with a $300k–$400k total compensation package consumes 3–5% of your Series A cash in the first year alone. That is a hard cost to defend when your primary value driver is still clinical or regulatory.
A fractional CRO lets you preserve runway while still signaling to your board and future investors that you take commercial readiness seriously. You get the strategy and accountability of a senior revenue leader without the fixed overhead. In 2027, when every dollar of burn is scrutinized, that flexibility is a competitive advantage.
What a Fractional CRO Actually Does for a Pre-Commercial Biotech
Do not expect a fractional CRO to cold-call physicians or manage a CRM queue. Their job is to build the commercial blueprint. Typical deliverables include:
- Go-to-market strategy: Which indication, which prescriber segment, which channel (specialty pharmacy, hospital system, group purchasing organization). They will pressure-test your assumptions against real market data.
- Revenue model and pricing: Help you set a price that works for payers, patients, and your margin targets. They will model scenarios for reimbursement timelines.
- Sales process design: Define the stages from initial KOL contact to formulary inclusion. Create a lead qualification framework and a forecasting methodology that your future VP of Sales can inherit.
- Team blueprint: Specify the roles, headcount, and ramp-up timeline for a commercial team. This becomes the hiring plan you hand to your full-time CRO later.
- Investor narrative: Translate your clinical data into a revenue story that Series B investors can underwrite. This alone can justify the fractional CRO's fee.
Fractional CRO vs. VP of Sales: Which Do You Need?
Many founders confuse the two. A VP of Sales is a line manager who owns quota, runs a team, and closes deals. A fractional CRO is a strategic advisor who designs the system the VP of Sales will eventually run. In a Series A biotech, you almost never need a VP of Sales first—you need the system.
If you hire a VP of Sales before you have a validated sales process, you will likely pay a high salary for someone who spends their first six months doing the strategic work a fractional CRO could have done in two months at half the cost. Worse, you may burn through cash building a sales team that sells the wrong thing to the wrong segment.
The fractional CRO's job is to make the VP of Sales's eventual job easier and more effective. They de-risk the commercial bet before you make the full-time hire.
How to Find a Strong Fractional CRO for Biotech
The supply of experienced fractional CROs has grown significantly since 2023, but biotech-specific experience remains thin. Most fractional CROs come from SaaS, fintech, or B2B services. That is not automatically disqualifying—commercial architecture skills transfer—but you should probe for:
- Reimbursement fluency: Do they understand Medicare Part B vs. Part D, medical benefit vs. pharmacy benefit, and the role of specialty pharmacy?
- KOL engagement: Have they designed a key opinion leader engagement plan? Do they know how to segment prescribers by volume and influence?
- Channel economics: Can they model the cost of a specialty pharmacy distribution vs. a limited-distribution network?
You will likely need to search nationally, not locally. Strong fractional CROs work remote or hybrid. Evaluate candidates from the Pavilion community, RevOps Co-op, and the CRO Syndicate network. Ask for references from biotech or medtech companies that were pre-commercial when they started.
The Cost Breakdown: What You Are Really Paying For
The monthly fee of $8k–$18k for 8–12 days is not cheap on a per-day basis ($800–$1,500/day). But compare it to a full-time CRO: $25k–$40k per month in base salary, plus benefits, plus the opportunity cost of a 3–6 month ramp-up. The fractional CRO starts delivering on day one because they are hired for a specific scope of work, not a vague "lead revenue" mandate.
Equity is typically 0.5–2% over 2 years, with a 1-year cliff. This is less than a full-time CRO's 1–3% over 4 years, which reflects the lower commitment and risk. Some fractional CROs will accept a higher equity component in exchange for lower cash, which can be attractive if you are extremely capital-constrained.
Do not accept a fractional CRO who demands a multi-year contract. The whole point of fractional is flexibility. A 30-day out clause protects you if the commercial timeline shifts (e.g., a clinical delay) or if the fit is wrong.
FAQ
How do I know if I am ready for a fractional CRO? You are ready if you have a clear commercial milestone (e.g., FDA approval, Series B raise, first product launch) that is 6–24 months away, and you currently have no revenue leader or a junior person who needs strategic direction. If you already have a VP of Sales who is struggling, a fractional CRO can coach them, but the fit is riskier.
Will a fractional CRO attend board meetings? Yes, if you ask. Most will attend monthly board meetings and prepare a commercial dashboard. This is often a key value—they give investors confidence that commercial readiness is being managed professionally.
Can a fractional CRO help with fundraising? Absolutely. A well-designed revenue model and go-to-market plan can differentiate your Series B pitch. Many fractional CROs have experience building the financial models and narratives that venture investors expect.
What if I need more than 12 days per month? You can often negotiate a "scale-up" clause—e.g., 15 days per month at a slightly higher rate. If you consistently need 15+ days, you should probably hire a full-time CRO or VP of Sales. The fractional model breaks down when the workload exceeds ~60% of a full-time role.
How do I transition from fractional to full-time? Agree on the trigger event in your initial contract. Common triggers: Series B close, first commercial sale, or a specific pipeline threshold (e.g., $5M qualified pipeline). The fractional CRO should document everything—process, dashboards, key relationships—so the transition is seamless. Some fractional CROs will convert to full-time, but many prefer to remain fractional. Plan for a handoff, not a conversion.
Sources
- Pavilion – Executive community for revenue leaders
- RevOps Co-op – Revenue operations community
- Harvard Business Review – Articles on fractional leadership and organizational design
- First Round Review – Startup leadership and hiring playbooks
- SaaStr – SaaS and subscription business insights
- LinkedIn – Professional network for vetting fractional CRO candidates
People also search for: fractional cro · hire a fractional cro · fractional cro near me · fractional cro cost